2012-10-04 17:36:16 - New Pharmaceuticals market report from Global Markets Direct: "Diabetes - Pipeline Review, H2 2012"

Global Markets Direct's, 'Diabetes - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Diabetes, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetes. Diabetes - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


Full Report Details at

- www.fastmr.com/prod/468350_diabetes_pipeline_review_h2_2012.aspx


Scope

* A snapshot of the global therapeutic scenario for Diabetes.
* A review of the Diabetes products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Diabetes pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Diabetes.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Diabetes pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Diabetes Overview
Therapeutics Development
An Overview of Pipeline Products for Diabetes
Diabetes Therapeutics under Development by Companies
Diabetes Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Diabetes Therapeutics - Products under Development by Companies
Diabetes Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Diabetes Therapeutics Development
Bristol-Myers Squibb Company
Baxter International Inc.
F. Hoffmann-La Roche Ltd.
Sanofi-Aventis
Eli Lilly and Company
Athersys, Inc.
Daiichi Sankyo Company, Ltd
Euroscreen S.A.
Cytokine PharmaSciences, Inc.
Takeda Pharmaceutical Company Limited
Meytav Technological Incubator
Ipsen S.A.
Piramal Healthcare Limited
Amylin Pharmaceuticals, Inc.
Astellas Pharma Inc.
Biocon Limited
Rigel Pharmaceuticals, Inc.
Sigma-Tau S.p.A.
Zydus Cadila Healthcare Limited
Biodel Inc.
Halozyme Therapeutics
Access Pharmaceuticals, Inc.
Genfit
Ligand Pharmaceuticals Incorporated
Lupin Limited
NexMed, Inc.
Oramed Pharmaceuticals, Inc.
Orchid Chemicals & Pharmaceuticals Ltd
Yuhan Corporation
Array BioPharma Inc.
XOMA Ltd.
Torrent Pharmaceuticals Limited
Choongwae Pharma Corp
Hanall Pharmaceutical Co., Ltd.
HYUNDAI PHARM. CO., LTD.
Suven Life Sciences Ltd.
Galapagos NV
Proximagen Neuroscience plc.
Transgene Biotek Ltd
Angelini Group
Betagenon AB
Biotecnol SA
Jenrin Discovery, Inc.
Phosphagenics Limited
Xenon Pharmaceuticals Inc.
Spherix Incorporated
Ambrx, Inc.
Five Prime Therapeutics, Inc.
GP Pharm, S.A.
Conatus Pharmaceuticals Inc.
MSM Protein Technologies, Inc.
Zealand Pharma A/S
Indus Biotech Private Limited
Theracos, Inc.
Vantia Therapeutics
Omeros Corporation
Aegis Therapeutics, LLC
Peptron, Inc.
Immunocore Limited.
Kalypsys, Inc.
PepTcell Limited
Limerick BioPharma, Inc.
Glucox Biotech
Diakron Pharmaceuticals, Inc.
Verva Pharmaceuticals Limited
Adocia
Amplimmune, Inc.
Ascendis Pharma A/S
Signum Biosciences, Inc.
PharmaIN Corporation
AUS Bio Limited
Advancell
Rhythm Pharmaceuticals
Diabetes - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Drug Profiles
insulin detemir - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Insulin glargine recombinant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
sitagliptin phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
metreleptin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Research and Development Brief
Licensing and Collaboration

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468350&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.